Abstract
To the Editor: With the advent of biologic treatments for psoriasis, well-designed clinical trials are critical to provide safety and efficacy data. Differences in psoriasis susceptibility due to heterogenous genetic profiles between demographic groups1 highlight the importance of equitably representing the overall disease population in clinical trials.2 Although psoriasis prevalence is greatest among White patients,3 existing data suggest that psoriasis may be more severe among ethnoracial minority groups.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
